文献速递垂体与肾上腺疾病

PANOMEN-3预测模型对垂体瘤复发和进展的验证与局限性

Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为多中心国家病例对照研究,纳入1143例随访至少5年的垂体瘤患者,验证PANOMEN-3分类对肿瘤复发/进展的预测能力。中位随访8.8年,253例出现复发或进展。模型诊断准确率75.6%(95%CI 0.716-0.796),复发/进展率随分级升高而增加(0级2.5%、1级10.3%、2级33.7%、3级33.3%,P<.001)。作者认为该模型可能有助于指导西班牙人群垂体瘤的预后和治疗。

要点

  • PANOMEN-3模型预测垂体瘤复发/进展的准确率为75.6%(95%CI 0.716-0.796)。
  • 复发/进展率随PANOMEN-3分级升高而增加:0级2.5%、1级10.3%、2级33.7%、3级33.3%(P<.001)。
  • 残余肿瘤(HR 2.20)、遗传综合征(HR 5.15)和活跃分泌状态(HR 1.80)是模型中最重要的变量。

核心结论

  • PANOMEN-3小组提出的预测模型可能有助于指导西班牙人群垂体瘤的预后和治疗,因其对手术和非手术患者的肿瘤/生化复发和/或进展具有良好的预测准确率。

研究设计与样本

  • 多中心国家病例对照研究,纳入随访至少5年的垂体瘤患者,共1143例;814例接受垂体手术,其余329例接受积极监测或药物治疗。

主要发现

  • 中位随访8.8年(范围5-29.8年),253例出现肿瘤复发或生化/影像学进展(病例组),其余890例为对照组。
  • 从垂体瘤诊断到复发的中位随访时间为7.2±5.4年。
  • PANOMEN-3模型预测复发/进展的诊断准确率为75.6%(95%CI 0.716-0.796)。
  • 残余肿瘤(HR 2.20,P<.001)、遗传综合征(HR 5.15,P=.026)和活跃分泌状态(HR 1.80,P=.021)是该模型中最重要的变量。
  • 复发/进展率随PANOMEN-3分级升高而增加:0级2.5%、1级10.3%、2级33.7%、3级33.3%(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It has been proposed that the PANOMEN-3 classification may be useful to guide the prognosis and therapy of patients with pituitary tumors (PTs). However, the model has not yet been validated to date in order to assess its usefulness in routine clinical practice. OBJECTIVE: The aim of our study was to validate the classification proposed by the PANOMEN-3 group for the prediction of tumor recurrence/progression in PTs. METHODS: Multicenter national case-control study of patients with PTs followed for at least 5 years. Kaplan-Meier curves were used to assess the time to tumor recurrence/progression. Univariate and multivariate Cox regression analyses were used to estimate the hazard ratio (HR) and prognostic capacity of the classification proposed by the PANOMEN-3 group. RESULTS: A total of 1143 patients were included. Pituitary surgery was performed in 814 patients and the remaining 329 patients were followed with active surveillance or medical treatment. After a median follow-up of 8.8 years (5-29.8), 253 patients experienced tumor recurrence or biochemical/radiological progression and were classified as cases. The other 890 patients were classified as controls. The mean follow-up from PT diagnosis to recurrence was 7.2 ± 5.4 years. The diagnostic accuracy of the PANOMEN-3 model to predict recurrence/progression was 75.6% (95% CI 0.716-0.796). Residual tumor (HR 2.20, P < .001), a hereditary syndrome (HR 5.15, P = .026), and active secretory status (HR 1.80, P = .021) were the most important variables in this model. Recurrence/progression rate increased with increasing PANOMEN-3 grade (2.5% in grade 0; 10.3% in grade 1, 33.7% in grade 2, and 33.3% in grade 3; P < .001). CONCLUSION: The predictive model proposed by the PANOMEN-3 group may be useful to guide the prognosis and therapy of PTs in the Spanish population since it offers a good accuracy to predict tumoral/biochemical recurrence and/or progression in operated and nonoperated patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Araujo-Castro M, Menéndez Torre E, Lozano-Aida C, et al. Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors. J Clin Endocrinol Metab. 2025. PMID: 40277238. doi:10.1210/clinem/dgaf252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。